Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002550 · ClinicalTrials.gov registry record · Phase 3

Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

A Phase 3 study, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 3
Development phase
429
Enrollment target

NCT00002550: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.

NCT00002550 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 429 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002550, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
429 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy plus radiation therapy is more effective with or without surgery for lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combining cisplatin, etoposide, and radiation therapy with or without surgery in treating patients who have stage IIIA non-small cell lung cancer.

Interventions

  • DRUG cisplatin
  • DRUG etoposide
  • PROCEDURE conventional surgery
  • RADIATION radiation therapy

Trial Details

FieldValue
Enrollment Target 429 participants
Start Date 1994-03
Est. Completion 2013-11
Phase Phase 3
Radiation Therapy Oncology Group

144 total trials

What the finished NCT00002550 record still lists

NCT00002550 is an interventional study that assigns participants to a tested intervention. The registered 429 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.

NCT00002550 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002550 about?

NCT00002550 is a clinical study titled "Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy plus radiation therapy is more effective with or without surgery for lu...

What is the current status of trial NCT00002550?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 1994-03. Estimated completion is 2013-11.

What interventions are being tested in trial NCT00002550?

The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT00002550?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00002550's enrollment target sits among peer trials

429 878th of 2000 higher than 1,123 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05932862 · 429 participants · Phase 1

    A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

  • NCT05327023 · 430 participants · Phase 1

    Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

  • NCT05457985 · 430 participants · NA

    Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers

  • NCT05532982 · 430 participants

    Parkinson's Disease in Asian Americans

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002550, the US trial registry maintained by the National Library of Medicine. NCT00002550 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.